Mountain View, California-based ReCode Therapeutics announced a research collaboration with an undisclosed gene editing company to develop a CFTR-correcting genetic therapy for cystic fibrosis (CF), backed by new funding from the Cystic Fibrosis Foundation (CFF). The three-party arrangement combines ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform with the partner's gene editing technology, with the goal of advancing one or more development candidates toward clinical development and commercialization. The identity of the gene editing partner was not disclosed in the announcement.
Under the collaboration structure, ReCode contributes its SORT LNP platform, which modifies LNP formulation composition to redirect delivery away from the liver toward extrahepatic tissues including lung epithelial cells — the relevant target for CFTR correction. The unnamed partner contributes its gene editing technology, described as capable of delivering a new class of curative genetic therapies. No named drug candidate, program code, or investigational new drug filing has been disclosed; the collaboration is at the preclinical research stage. The CFF's new funding (specifics not disclosed) is specifically committed to support this gene editing collaboration, in addition to the Foundation's prior investments in ReCode's mRNA program.
The collaboration extends a prior partnership between ReCode and Intellia Therapeutics (Nasdaq: NTLA) announced in February 2024, in which Intellia contributed its CRISPR-based DNA writing technology while ReCode contributed the SORT LNP platform to jointly pursue CFTR-correcting gene editing for lung delivery — a structurally identical arrangement to the current announcement. In November 2024, the CFF committed up to USD 15 million to support that ReCode-Intellia gene correction program. The CFF has separately committed up to USD 24 million to Cambridge, Massachusetts-based Prime Medicine (Nasdaq: PRME) for a prime editing-based CFTR program targeting the G542X nonsense mutation, underscoring the Foundation's role as the most active non-dilutive funder of genetic medicine approaches in CF. ReCode's lead clinical program, RCT2100, an inhaled CFTR mRNA therapy formulated with the SORT LNP platform, is currently in a fully enrolled Phase IIa study with data expected in Q4 2026; the company also reported data from its RCT1100 program for primary ciliary dyskinesia at the American Thoracic Society Congress in May 2026.
Access the AllSci platform to explore the science behind the news.
Spot something wrong? Report an issue with this article